Dr. Rula AlMofti

Assistant professor KSAUH.

Medical oncology Fellowship program director, Ngh Jeddah.

Consultant Adult medical Oncologist

Princess Noorah Oncology center , KAMC , Jeddah

10 : 40 – 10 : 50

24 June | 2023 Day 2

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.